Completed PHASE4 INTERVENTIONAL 2-arm NCT02345213

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

Sponsor: Eisai Co., Ltd.

Conditions Dementia, Lewy Body Lewy Body Disease

Interventions E2020 Placebo

Updated 8 times since 2017 Last updated: Jan 7, 2019 Started: Mar 1, 2015 Primary completion: May 15, 2017 Completion: Mar 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02345213, this PHASE4 trial focuses on Dementia, Lewy Body and Lewy Body Disease and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2019 — Jan 2021 [monthly]

Completed PHASE4
Sep 2018 — Feb 2019 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE4
Jan 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Jan 2017 — Jan 2018 [monthly]

Recruiting PHASE4

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Co., Ltd.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saitama, Japan